keyword
MENU ▼
Read by QxMD icon Read
search

Progression-free survival

keyword
https://www.readbyqxmd.com/read/28107595/chromogranin-a-and-neurone-specific-enolase-variations-during-the-first-three-months-of-abiraterone-therapy-predict-outcomes-in-patients-with-metastatic-castration-resistant-prostate-cancer
#1
Liancheng Fan, Yanqing Wang, Chi Chenfei, Jiahua Pan, Xun Shangguan, Zhixiang Xin, Jianian Hu, Zhou Lixin, Baijun Dong, Wei Xue
OBJECTIVE: To determine the prognostic factors of circulating chromogranin A (CgA) and neurone-specific enolase (NSE) variations during the first 3 months of abiraterone Acetate (AA) treatment in metastatic castration-resistant prostate cancer (mCRPC) patients. PATIENTS AND METHODS: The serum levels of CgA, NSE were measured at baseline and after 3 months of AA treatments in 40 mCRPC patients. Outcome measures were PSA progression-free survival (PSA-PFS), radiographic PFS (rPFS) and overall survival (OS)...
January 20, 2017: BJU International
https://www.readbyqxmd.com/read/28107187/peripheral-blood-lymphocyte-to-monocyte-ratio-recovery-from-low-levels-at-diagnosis-after-completion-of-first-line-therapy-predicts-good-clinical-outcomes-in-patients-with-diffuse-large-b-cell-lymphoma
#2
Shujuan Zhou, Linglong Xu, Yongyong Ma, Liyuan Tang, Yu Zhang, Yifen Shi, Lan Sun, Yi Chen, Bin Liang, Yuhong Zhou, Kang Yu, Jianping Shen
We retrospectively analyzed LMR at diagnosis and at completion of first-line therapy and prognosis in173 patients with DLBCL from 2005 to 2016. We found that patients with an LMR < 3.2 at diagnosis, as well as at completion of first-line therapy, had significantly lower PFS and OS rates than those with an LMR ≥ 3.2 (P<0.05). Patients with LMR that recovered from the low level at diagnosis showed superior overall survival (OS) (P=0.000) and progression-free survival (PFS) (P=0.001) compared with patients who failed to achieve a higher value at the completion of therapy...
January 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28107090/cost-effectiveness-analysis-in-the-spanish-setting-of-the-peak-trial-of-panitumumab-plus-mfolfox6-compared-with-bevacizumab-plus-mfolfox6-for-first-line-treatment-of-patients-with-wild-type-ras-metastatic-colorectal-cancer
#3
Fernando Rivera, Manuel Valladares, Salvador Gea, Noemí López-Martínez
OBJECTIVE: To assess the cost-effectiveness of panitumumab in combination with mFOLFOX6 (oxaliplatin, 5-fluorouracil and leucovorin) versus bevacizumab in combination with mFOLFOX6 as first-line treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC) in Spain. METHODS: A semi-Markov model was developed including the following health states: Progression free; Progressive disease: Treat with best supportive care; Progressive disease: Treat with subsequent active therapy; Attempted resection of metastases; Disease free after metastases resection; Progressive disease: after resection and relapse; Death...
January 20, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28106659/adenoid-cystic-carcinoma-evaluation-and-management-progress-with-optimism
#4
Patrick J Bradley
PURPOSE OF REVIEW: Adenoid cystic carcinoma (ACC) when diagnosed presents several diagnostic and treatment challenges. The standard treatment of surgery and postoperative radiotherapy has remained the standard of care for the past 3 decades. The purpose of this review is to update what's been reported and what's new since the last review in 2004. RECENT FINDINGS: As accurate a histological diagnosis and staging of disease should be achieved prior to commencing any treatment...
January 18, 2017: Current Opinion in Otolaryngology & Head and Neck Surgery
https://www.readbyqxmd.com/read/28105753/efficacy-and-safety-of-high-dose-chemotherapy-with-autologous-stem-cell-transplantation-in-senior-versus-younger-adults-with-newly-diagnosed-multiple-myeloma
#5
Li-Wen Huang, Wendi Bacon, Constance Cirrincione, Bercedis Peterson, Gwynn Long, David Rizzieri, Keith M Sullivan, Kelly Corbet, Mitchell Horwitz, Nelson Chao, Cristina Gasparetto, Sascha A Tuchman
We retrospectively studied 340 fit patients with multiple myeloma (MM) who underwent autologous stem cell transplantation (ASCT). We hypothesized that progression-free survival (PFS) of older patients was non-inferior to that of younger patients after ASCT. Our null hypothesis was that the PFS hazard ratio (HR) for a 5-year increase in age was ≥1.05; the alternative (non-inferiority) hypothesis was that the HR was ≤1. The observed HR was 0.94 (95% confidence interval [CI] 0.86-1.03); since the CI upper bound was <1...
January 19, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28105602/ibrutinib-a-review-in-chronic-lymphocytic-leukaemia
#6
Emma D Deeks
Ibrutinib (Imbruvica(®)) is an oral irreversible inhibitor of Bruton's tyrosine kinase, a B-cell receptor (BCR) signalling kinase expressed by various haematopoietic cells, B-cell lymphomas and leukaemias. The drug is indicated for the treatment of certain haematological malignancies, including chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL), which are the focus of this review. In phase III CLL/SLL trials, ibrutinib monotherapy was more effective than chlorambucil in the first-line treatment of elderly patients (RESONATE-2) and more effective than ofatumumab in previously-treated adults (RESONATE)...
January 20, 2017: Drugs
https://www.readbyqxmd.com/read/28105297/follicular-lymphoma-the-management-of-elderly-patient
#7
REVIEW
Alessia Castellino, Elisa Santambrogio, Maura Nicolosi, Barbara Botto, Carola Boccomini, Umberto Vitolo
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma, which typically affects mature adults and elderly, whose median age at diagnosis is 65 years. The natural history of FL appears to have been favorably impacted by the introduction of Rituximab. Randomized clinical trials demonstrated that the addition of rituximab to standard chemotherapy induction has improved the overall survival and new strategies of chemo-immunotherapy, such as Bendamustine combined with Rituximab, showed optimal results on response and reduced hematological toxicity, becoming one of the standard treatments, particularly in elderly patients...
2017: Mediterranean Journal of Hematology and Infectious Diseases
https://www.readbyqxmd.com/read/28105178/prognostic-relevance-of-samsn1-expression-in-gastric-cancer
#8
Mitsuro Kanda, Dai Shimizu, Satoshi Sueoka, Shuji Nomoto, Hisaharu Oya, Hideki Takami, Kazuhiro Ezaka, Ryoji Hashimoto, Yuri Tanaka, Daisuke Kobayashi, Chie Tanaka, Suguru Yamada, Tsutomu Fujii, Goro Nakayama, Hiroyuki Sugimoto, Masahiko Koike, Michitaka Fujiwara, Yasuhiro Kodera
The prognosis for patients with advanced gastric cancer (GC) remains poor. The identification of biomarkers relevant to the recurrence and metastasis of GC is advantageous for stratifying patients and proposing novel molecular targets. In the present study the oncological roles of SAM domain, SH3 domain and nuclear localization signals 1 (SAMSN1), a mediator of B-cell function, were elucidated in GC. The expression and methylation status of SAMSN1 were investigated in a panel of 11 GC cell lines. Immunohistochemical staining was performed to determine the pattern of SAMSN1 protein expression in gastric tissues...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28105168/relationship-between-mir-7-expression-and-treatment-outcomes-with-gefitinib-in-non-small-cell-lung-cancer
#9
Kun Mou, Weiwei Gu, Cuihua Gu, Jinzhong Zhang, Wenjie Qwang, Gang Ren, Jing Tian
The aim of the present study was to assess the effects of gefitinib chemotherapy on the serum levels of miR-7 in patients with non-small cell lung cancer (NSCLC). A total of 126 patients were enrolled in the present study (stage I-II, n=54 and stage III-IV, n=72). Patients with stage I-II NSCLC underwent surgery in combination with gefitinib chemotherapy, whereas only gefitinib chemotherapy was administered to patients with stage III-IV disease. Serum levels of miR-7 before and after treatment were measured with quantitative polymerase chain reaction using fluorogenic probes, and miR-7 positivity and scoring in resected specimens were determined by immunohistochemistry...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28104919/next-generation-flow-ngf-for-highly-sensitive-and-standardized-detection-of-minimal-residual-disease-in-multiple-myeloma
#10
J Flores-Montero, L S Flores, B Paiva, N Puig, Omar García-Sánchez, S Böttcher, V H J van der Velden, J-J Pérez-Morán, M-B Vidriales, R García-Sanz, C Jimenez, M González, J Martinez-López, A C Mateos, G-E Grigore, R Fluxá, R Pontes, J Caetano, L Sedek, M-C Del Cañizo, J Bladé, J-J Lahuerta, C Aguilar, A Bárez, A García-Mateo, J Labrador, P Leoz, C Aguilera-Sanz, J San-Miguel, M-V Mateos, B Durie, J J M van Dongen, A Orfao
Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of complete response (CR) in bone marrow (BM) of multiple myeloma (MM) after therapy. However, current flow-MRD has lower sensitivity than molecular methods and lacks standardization. Here we report on a novel next generation flow (NGF) approach for highly-sensitive and standardized MRD detection in MM. An optimized 2-tube 8-color antibody panel was constructed in five cycles of design-evaluation-redesign...
January 20, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28104820/immune-checkpoint-inhibitors-in-malignancies-with-mismatch-repair-deficiency-a-review-of-the-state-of-the-current-knowledge
#11
Ali Naboush, Christopher A J Roman, Iuliana Shapira
The use of immune checkpoint inhibitors to treat malignant tumors with microsatellite instability is an emerging new modality. This is based on the observations that these tumors may have a high mutation rate-thus a potential source of tumor-specific neoantigens-and harbor infiltrating cytotoxic T cells in response, suggesting that they may be particularly susceptible to immune checkpoint therapy. PUBMED and ASCO library were systematically reviewed to identify all relevant data that involved the use of immune checkpoint inhibitors in the treatment of cancers with microsatellite instability...
January 19, 2017: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
https://www.readbyqxmd.com/read/28104619/osimertinib-benefit-in-egfr-mutant-nsclc-patients-with-t790m-mutation-detected-by-circulating-tumour-dna
#12
J Remon, C Caramella, C Jovelet, L Lacroix, A Lawson, S Smalley, K Howarth, D Gale, E Green, V Plagnol, N Rosenfeld, D Planchard, M V Bluthgen, A Gazzah, C Pannet, C Nicotra, E Auclin, J C Soria, B Besse
BACKGROUND: Approximately 50% of Epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) will acquire resistance by the T790M mutation. Osimertinib is the standard of care in this situation. The present study assesses the efficacy of osimertinib when T790M status is determined in circulating cell-free tumour DNA (ctDNA) from blood samples in progressing advanced EGFR-mutant NSCLC patients. MATERIAL AND METHODS: ctDNA T790M mutational status was assessed by Inivata InVision(TM) (eTAm-Seq(TM)) assay in 48 EGFR-mutant advanced NSCLC patients with acquired resistance to EGFR TKIs without a tissue biopsy between April 2015 and April 2016...
January 18, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28104421/assessing-cancer-progression-and-stable-disease-after-neoadjuvant-chemotherapy-for-organ-confined-muscle-invasive-bladder-cancer
#13
Meera R Chappidi, Max Kates, Aaron Brant, Alexander S Baras, George J Netto, Phillip M Pierorazio, Noah M Hahn, Trinity J Bivalacqua
OBJECTIVE: To propose and validate a new approach to stratify clinically staged organ-confined muscle-invasive bladder cancer patients (cT2N0M0) that are pathologic non-responders to neoadjuvant chemotherapy (NAC) to better characterize NAC non-response. METHODS: We retrospectively identified radical cystectomy patients with cT2N0M0 disease at our institution (2005-2014) and in the National Cancer Database (NCDB, 2004-2012) for external validation. Patients were stratified as stable (pT2N0M0) or progressors (>pT2 and/or pN+)...
January 16, 2017: Urology
https://www.readbyqxmd.com/read/28104311/comprehensive-profiling-of-the-androgen-receptor-in-liquid-biopsies-from-castration-resistant-prostate-cancer-reveals-novel-intra-ar-structural-variation-and-splice-variant-expression-patterns
#14
Bram De Laere, Pieter-Jan van Dam, Tom Whitington, Markus Mayrhofer, Emanuela Henao Diaz, Gert Van den Eynden, Jean Vandebroek, Jurgen Del-Favero, Steven Van Laere, Luc Dirix, Henrik Grönberg, Johan Lindberg
BACKGROUND: Expression of the androgen receptor splice variant 7 (AR-V7) is associated with poor response to second-line endocrine therapy in castration-resistant prostate cancer (CRPC). However, a large fraction of nonresponding patients are AR-V7-negative. OBJECTIVE: To investigate if a comprehensive liquid biopsy-based AR profile may improve patient stratification in the context of second-line endocrine therapy. DESIGN, SETTING, AND PARTICIPANTS: Peripheral blood was collected from patients with CRPC (n=30) before initiation of a new line of systemic therapy...
January 16, 2017: European Urology
https://www.readbyqxmd.com/read/28104035/-application-value-of-laparoscopic-radiofrequency-ablation-for-specific-location-hepatocellular-carcinoma
#15
H D Shi, X J Shi, H X Ma, Y R Liang, L Zhou, Y Shi
Objective: To investigate the therapeutic efficacy and safety of laparoscopic radiofrequency ablation (LRFA) for specific-location hepatocellular carcinoma. Methods: To retrospectively analyze 496 patients with specific-location hepatocellular carcinoma treated with LRFA from January 2010 to January 2015 in our hospital. There was a total of 652 hepatic lesions with a mean diameter of (2.8±1.3) cm including 397 cases with single lesion and 99 cases with multiple lesions. The hepatic lesions were adjacent to major hepatic vessels, hepatic hilar region, diaphragmatic dome, gallbladder, or gastrointestinal tract and on the surface of the liver, respectively...
January 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/28104028/-effect-of-hif-2%C3%AE-on-regulating-cdcp1-to-promote-hepatocellular-carcinoma-metastasis
#16
M Q Cao, J R Gao, J F Huang, A B You, Z G Guo, H Y Zhou, F Fang, W Zhang, X L Zhu, T Zhang
Objective: To investigate the effect of hypoxia inducible factor 2α (HIF-2α) on regulating CUB domain-containing protein 1 (CDCP1) and its role in hepatocellular carcinoma metastasis. Methods: HIF-2α-knocked down and HIF-2α-stably overexpressing cells (MHCC97H) were prepared by small interfering RNA (siRNA) and lentivirus transfection, respectively. The expression of CDCP1 protein and mRNA in the above cells was detected by western blot and real-time PCR. The effect of HIF-2α on cell invasion ability was determined by Transwell assay...
January 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/28103974/-phase-i-study-of-etoposide-and-cisplatin-chemotherapy-dose-escalation-%C3%A2-with-concurrent-twice-daily-radiotherapy-for-patients-%C3%A2-with-limited-stage-small-cell-lung-cancer
#17
Jing You, Huiming Yu, Maxiaowei Song, Chen Shi, Xiaohang Wang, Ye Zheng, Rong Yu, Anhui Shi, Guangying Zhu
BACKGROUND: Concurrent twice-daily radiotherapy with chemotherapy of EP regimen is one of the current standard treatments for limited-stage small cell lung cancer. However, the safely tolerated dose of standard chemotherapy for Chinese patients is not decided. This study was to evaluate the toxicity and the maximum tolerated dose (MTD) of etoposide and cisplatin concurrent with thoracic radiation therapy for patients with limited-stage small cell lung cancer. METHODS: Patients with histologically proven limited-stage small cell lung cancer (LS-SCLC) were eligible...
January 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28103970/-a-phase-i-ii-study-of-chemotherapy-concurrent-with-twice-daily-radiotherapy-%C3%A2-schedules-by-intensity-modulated-radiation-therapy-using-simultaneous-integrated-boost-for-limited-stage-small-cell-lung-cancer
#18
Jing You, Huiming Yu, Maxiaowei Song, Chen Shi, Xiaohang Wang, Ye Zheng, Rong Yu, Anhui Shi, Guangying Zhu
BACKGROUND: Twice-daily radiation concurrent with chemotherapy is one of the standard methods for limited-stage small cell lung cancer. The study was to evaluate the feasibility of chemotherapy concurrent with dose-escalating twice-daily radiotherapy by simultaneous integrated boost intensity-modulated radiation therapy (SIB-IMRT) approach in patients with limited-stage small cell lung cancer. METHODS: Patients with limited-stage small cell lung cancer were included, treated with twice-daily radiotherapy by SIB-IMRT concurrent with chemotherapy of etoposide plus cisplatin...
January 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28103953/microwave-ablation-is-as-effective-as-radiofrequency-ablation-for-very-early-stage-hepatocellular-carcinoma
#19
Yun Xu, Qiang Shen, Neng Wang, Pan-Pan Wu, Bin Huang, Ming Kuang, Guo-Jun Qian
BACKGROUND: Percutaneous radiofrequency ablation (RFA) is a first-line treatment for very-early-stage hepatocellular carcinoma (HCC), whereas the efficacy of percutaneous microwave ablation (MWA) for very-early-stage HCC remains unclear. The purpose of this study was to clarify this issue by comparing the safety and efficacy of percutaneous MWA with percutaneous RFA in treating very-early-stage HCC. METHODS: Clinical data of 460 patients who were diagnosed with very-early-stage HCC and treated with percutaneous MWA or RFA between January 2007 and July 2012 at the Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, in Shanghai, China were retrospectively analyzed...
January 19, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/28103919/prognostic-values-of-apoptosis-stimulating-p53-binding-protein-1-and-2-and-their-relationships-with-clinical-characteristics-of-esophageal-squamous-cell-carcinoma-patients-a-retrospective-study
#20
Xiao-Feng Xie, Qing Yang, Jun Chi, Xian-Zi Yang, Hui-Yun Wang, Guo-Liang Xu
BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is a leading cause of cancer-related death, and new prognostic biomarkers are urgently needed. Apoptosis-stimulating P53-binding protein 1 (ASPP1) and 2 (ASPP2) have been reported to play important roles in the development, progression, metastasis, and prognosis of cancers, but their roles in ESCC have not been elucidated. In this study, we examined the expression of ASPP1 and ASPP2 in ESCC to evaluate their prognostic values. METHODS: The protein expression of ASPP1, ASPP2, and P53 in 175 specimens of ESCC was detected using immunohistochemical staining; their expression in cancerous and noncancerous tissues was scored according to the staining intensity and the percentage of stained cells...
January 19, 2017: Chinese Journal of Cancer
keyword
keyword
119233
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"